News & Updates

Treatment with dulaglutide is both effective and safe in Asians with type 2 diabetes mellitus (T2DM), a recent meta-analysis has found.

Patients with concomitant chronic kidney disease (CKD) and type 2 diabetes (T2D) who are undergoing mineralocorticoid receptor blockade with finerenone are better protected against pneumonia and COVID-19, according to a secondary analysis of data from the FIDELITY trials.

Using a lower glycaemic threshold led to more diagnoses of gestational diabetes, though its impact on maternal and birth outcomes remains uncertain, results of the GEMS* trial showed.

Obese adults with weight-related complications who do not respond adequately to lifestyle interventions should be offered one of four anti-obesity medications, according to the new clinical practice guideline on pharmacological interventions released by the American Gastroenterological Association (AGA).

Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.

Obesity does not increase the likelihood of hospitalization among biologic-treated patients with inflammatory bowel disease (IBD), suggests a recent study.